QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (GAMMA)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Research Site
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Research Site
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- Research Site
-
Woodville South, South Australia, Australia, 5011
- Research Site
-
-
Victoria
-
Bentleigh East, Victoria, Australia, 3165
- Research Site
-
Parkville, Victoria, Australia, 3050
- Research Site
-
-
-
-
-
Innsbruck, Austria, 6020
- Research Site
-
Salzburg, Austria, 5020
- Research Site
-
Steyr, Austria, 4400
- Research Site
-
Wien, Austria, 1090
- Research Site
-
-
-
-
-
Bruxelles, Belgium, 1070
- Research Site
-
Charleroi, Belgium, 6000
- Research Site
-
Edegem, Belgium, 2650
- Research Site
-
Gent, Belgium, 9000
- Research Site
-
Leuven, Belgium, 3000
- Research Site
-
Libramont, Belgium, 6800
- Research Site
-
-
-
-
Bahia
-
Salvador, Bahia, Brazil, 40050-410
- Research Site
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-003
- Research Site
-
-
-
-
-
Sofia, Bulgaria, 1527
- Research Site
-
Sofia, Bulgaria, 1756
- Research Site
-
Sofia, Bulgaria, 1606
- Research Site
-
Varna, Bulgaria, 9010
- Research Site
-
-
-
-
-
Quebec, Canada, G1R 2J6
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Research Site
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- Research Site
-
Ottawa, Ontario, Canada, K1H 8L6
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Research Site
-
-
-
-
-
Brno, Czechia, 656 53
- Research Site
-
Brno, Czechia, 656 91
- Research Site
-
Hradec Kralove, Czechia, 500 05
- Research Site
-
Olomouc, Czechia, 775 20
- Research Site
-
Praha 2, Czechia, 128 08
- Research Site
-
Praha 5, Czechia, 150 06
- Research Site
-
-
-
-
-
Aalborg, Denmark, 9000
- Research Site
-
Herlev, Denmark, 2730
- Research Site
-
Odense, Denmark, 5000
- Research Site
-
-
-
-
-
Lahti, Finland, 15850
- Research Site
-
Tampere, Finland, 33521
- Research Site
-
Turku, Finland, 20521
- Research Site
-
-
-
-
-
Brest cedex, France, 29609
- Research Site
-
Clermont Ferrand Cedex 1, France, 63003
- Research Site
-
Pessac Cedex, France, 33604
- Research Site
-
-
-
-
-
Berlin, Germany, 13353
- Research Site
-
Dresden, Germany, 01307
- Research Site
-
Halle (Saale), Germany, 06120
- Research Site
-
Mainz, Germany, 55131
- Research Site
-
Mannheim, Germany, 68167
- Research Site
-
Marburg, Germany, 35043
- Research Site
-
Villingen-Schwenningen, Germany, 78050
- Research Site
-
-
-
-
-
Athens, Greece, 11527
- Research Site
-
Heraklion, Greece, 71110
- Research Site
-
Patra, Greece, 26500
- Research Site
-
Thessaloniki, Greece, 56429
- Research Site
-
-
-
-
-
Kowloon, Hong Kong
- Research Site
-
Sha Tin, Hong Kong
- Research Site
-
Tuen Mun, Hong Kong
- Research Site
-
-
-
-
-
Budapest, Hungary, 1062
- Research Site
-
Budapest, Hungary, 1097
- Research Site
-
Debrecen, Hungary, 4012
- Research Site
-
Gyor, Hungary, 9023
- Research Site
-
Miskolc, Hungary, 3526
- Research Site
-
-
-
-
-
Genova, Italy, 16132
- Research Site
-
Messina, Italy, 98125
- Research Site
-
Napoli, Italy, 80131
- Research Site
-
-
-
-
-
Tokyo, Japan, 104-0045
- Research Site
-
-
Aichi
-
Nagoya-city, Aichi, Japan, 464-8681
- Research Site
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Research Site
-
-
Kanagawa
-
Yokohama-city, Kanagawa, Japan, 241-0815
- Research Site
-
-
Tokyo
-
Mitaka-city, Tokyo, Japan, 181-8611
- Research Site
-
-
-
-
-
Seoul, Korea, Republic of, 135-710
- Research Site
-
Seoul, Korea, Republic of, 120-752
- Research Site
-
Seoul, Korea, Republic of, 138-736
- Research Site
-
Seoul, Korea, Republic of, 110-744
- Research Site
-
Seoul, Korea, Republic of, 152-703
- Research Site
-
-
-
-
-
Kaunas, Lithuania, 50009
- Research Site
-
Vilnius, Lithuania, 08660
- Research Site
-
-
-
-
-
Amsterdam, Netherlands, 1081 HV
- Research Site
-
Eindhoven, Netherlands, 5623 EJ
- Research Site
-
Groningen, Netherlands, 9713 GZ
- Research Site
-
Leiden, Netherlands, 2333 ZA
- Research Site
-
-
-
-
-
Gdansk, Poland, 80-952
- Research Site
-
Konin, Poland, 62-500
- Research Site
-
Lodz, Poland, 93-509
- Research Site
-
Poznan, Poland, 61-485
- Research Site
-
Warszawa, Poland, 04-141
- Research Site
-
Warszawa, Poland, 02-097
- Research Site
-
Warszawa, Poland, 04-125
- Research Site
-
-
-
-
-
Barreiro, Portugal, 2830-094
- Research Site
-
Lisboa, Portugal, 1649-035
- Research Site
-
Lisboa, Portugal, 1099-023
- Research Site
-
Porto, Portugal, 4200-319
- Research Site
-
Porto, Portugal, 4200-072
- Research Site
-
-
-
-
-
Bucharest, Romania, 022328
- Research Site
-
Cluj Napoca, Romania, 400015
- Research Site
-
Cluj-Napoca, Romania, 400015
- Research Site
-
Sibiu, Romania, 550245
- Research Site
-
-
-
-
-
Moscow, Russian Federation, 115478
- Research Site
-
Moscow, Russian Federation, 119992
- Research Site
-
Saint Petersburg, Russian Federation, 191104
- Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Research Site
-
Belgrade, Serbia, 11080
- Research Site
-
Sremska Kamenica, Serbia, 21204
- Research Site
-
-
-
-
-
Bardejov, Slovakia, 085 01
- Research Site
-
Bratislava, Slovakia, 833 10
- Research Site
-
Kosice, Slovakia, 041 91
- Research Site
-
Nitra, Slovakia, 950 01
- Research Site
-
Poprad, Slovakia, 058 01
- Research Site
-
-
-
-
-
Ljubljana, Slovenia, 1000
- Research Site
-
Ljubljana, Slovenia, 1525
- Research Site
-
-
-
-
-
Madrid, Spain, 28034
- Research Site
-
Madrid, Spain, 28050
- Research Site
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Research Site
-
-
Cataluña
-
Badalona, Cataluña, Spain, 08916
- Research Site
-
Barcelona, Cataluña, Spain, 08035
- Research Site
-
Barcelona, Cataluña, Spain, 08036
- Research Site
-
-
Comunidad Valenciana
-
Elche, Comunidad Valenciana, Spain, 03203
- Research Site
-
Valencia, Comunidad Valenciana, Spain, 46010
- Research Site
-
-
-
-
-
Eskilstuna, Sweden, 631 88
- Research Site
-
Uppsala, Sweden, 751 85
- Research Site
-
-
-
-
-
Basel, Switzerland, 4031
- Research Site
-
Geneva 14, Switzerland, 1211
- Research Site
-
Winterthur, Switzerland, 8401
- Research Site
-
-
-
-
Taipei
-
Taipei City, Taipei, Taiwan, 10002
- Research Site
-
-
-
-
-
Belfast, United Kingdom, BT9 7AB
- Research Site
-
Birmingham, United Kingdom, B9 5SS
- Research Site
-
Cottingham, United Kingdom, HU16 5JQ
- Research Site
-
Leicester, United Kingdom, LE1 5WW
- Research Site
-
Manchester, United Kingdom, M20 4BX
- Research Site
-
Northampton, United Kingdom, NN1 5BD
- Research Site
-
-
-
-
California
-
Fullerton, California, United States, 92835
- Research Site
-
La Jolla, California, United States, 92093-0957
- Research Site
-
Los Angeles, California, United States, 90095
- Research Site
-
Los Angeles, California, United States, 90095-1772
- Research Site
-
Rancho Mirage, California, United States, 92270
- Research Site
-
Redondo Beach, California, United States, 90277
- Research Site
-
Santa Maria, California, United States, 93454
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Research Site
-
Harvey, Illinois, United States, 60426
- Research Site
-
Quincy, Illinois, United States, 62301
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Research Site
-
Boston, Massachusetts, United States, 02215
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Research Site
-
Grand Rapids, Michigan, United States, 49503
- Research Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Research Site
-
-
Oregon
-
Bend, Oregon, United States, 97701
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Research Site
-
Providence, Rhode Island, United States, 02906
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
- Research Site
-
-
Texas
-
Fort Worth, Texas, United States, 76177
- Research Site
-
Paris, Texas, United States, 75460-5004
- Research Site
-
-
Virginia
-
Abingdon, Virginia, United States, 24211
- Research Site
-
-
Washington
-
Spokane Valley, Washington, United States, 99216
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Untreated metastatic adenocarcinoma of the pancreas
- Adequate hematologic, renal and liver function
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
Exclusion Criteria:
- Prior chemotherapy or radiotherapy for pancreatic cancer
- Central nervous system metastases
- External biliary drain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo + gemcitabine
Arm 1: AMG 479-placebo IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
|
gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
Other Names:
Placebo administered intravenously on days 1 and 15 of a 28 day cycle
|
|
Experimental: AMG 479 12 mg/kg dose + gemcitabine
Arm 2: AMG 479 12 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
|
AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
Other Names:
|
|
Experimental: AMG 479 20 mg/kg + gemcitabine
Arm 3: AMG 479 20 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
|
AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine if the Treatment of AMG 479 at 12 mg/kg and/or 20 mg/kg in Combination With Gemcitabine Improves Overall Survival as Compared With Placebo in Combination With Gemcitabine in Subjects With Metastatic Adenocarcinoma of the Pancreas
Time Frame: From randomization up to 20 months
|
The primary endpoint of the study was OS, defined as the time from randomization to death.
|
From randomization up to 20 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression free survival
Time Frame: After 825 subjects randomized + 24 months
|
After 825 subjects randomized + 24 months
|
|
Objective response rate
Time Frame: After 825 subjects randomized + 24 months
|
After 825 subjects randomized + 24 months
|
|
Time to disease progression
Time Frame: After 825 subjects randomized + 24 months
|
After 825 subjects randomized + 24 months
|
|
Disease control rate
Time Frame: After 825 subjects randomized + 24 months
|
After 825 subjects randomized + 24 months
|
|
Number of subjects with adverse events
Time Frame: After 825 subjects randomized + 24 months
|
After 825 subjects randomized + 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: NantKWest Clinical Review Team, ImmunityBio, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Neoplastic Processes
- Pancreatic Diseases
- Neoplasms
- Neoplasm Metastasis
- Adenocarcinoma
- Pancreatic Neoplasms
- Endocrine Gland Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Antibodies, Monoclonal
- Gemcitabine
Other Study ID Numbers
Other Study ID Numbers
- 20060540
- GAMMA
- QUILT-2.014 (Other Identifier: NantCell, Inc.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.